Regeneron

YTD

ALL

Trade Regeneron 24 hours a day, five days a week on Robinhood.

Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.

About REGN

Regeneron Pharmaceuticals, Inc. is a biotechnology company, which engages in the discovery, invention, development, manufacture, and commercialization of medicines. Its product portfolio includes the following brands: Dupixent, Evkeeza, Eylea, Inmazeb, and Kevzara.

CEO

Leonard S. Schleifer

CEOLeonard S. Schleifer

Employees

15,410

Employees15,410

Headquarters

Tarrytown, New York

HeadquartersTarrytown, New York

Founded

1988

Founded1988

Employees

15,410

Employees15,410

REGN Key Statistics

Market cap

82.53B

Market cap82.53B

Price-Earnings ratio

19.87

Price-Earnings ratio19.87

Dividend yield

0.46%

Dividend yield0.46%

Average volume

768.81K

Average volume768.81K

High today

—

High today—

Low today

—

Low today—

Open price

$805.23

Open price$805.23

Volume

117.00

Volume117.00

52 Week high

$859.34

52 Week high$859.34

52 Week low

$541.00

52 Week low$541.00

Stock Snapshot

With a market cap of 82.53B, Regeneron(REGN) trades at $800.00. The stock has a price-to-earnings ratio of 19.87 and currently yields dividends of 0.46%.

Regeneron(REGN) stock opened on 2026-09-24 at $805.23. The price climbed to — and dipped to —.

Regeneron(REGN) shares are trading with a volume of 117, against a daily average of 768.81K.

In the last year, Regeneron(REGN) shares hit a 52-week high of $859.34 and a 52-week low of $541.00.

REGN News

Simply Wall St 14h

Regeneron Pharmaceuticals Could Be 4% Undervalued Following Class Action Filing

Regeneron Pharmaceuticals (REGN) is back in focus after investors were hit with news of a securities class action related to its Phase III Fianlimab Libtayo tri...

Nasdaq 2d

Is Regeneron Stock a Bargain Below $800?

Key Points Regeneron's latest financial results were strong. The company is finding ways to overcome a recent patent cliff. Despite more challenges on the ho...

TipRanks 6d

Itepekimab COPD Extension Trial Completion: What It Means for Regeneron and Sanofi

Regeneron Pharmaceuticals (REGN), Sanofi (SNYNF) announced an update on their ongoing clinical study. The extension study “A Double-blinded Extension Study to...

Analyst ratings

60%

of 30 ratings

Buy

60%

Hold

33.3%

Sell

6.7%

More REGN News

Simply Wall St 7d

How Investors Are Reacting To Regeneron Pharmaceuticals Stock Trial Disclosure Lawsuits

Regeneron Pharmaceuticals is facing federal securities class action lawsuits filed in September 2026 that allege misleading disclosures about the Phase III Fian...

People also own

Based on the portfolios of people who own REGN. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.